29 results about "Drugs evaluations" patented technology

The invention requests to protect a drug comprehensive evaluation system based on machine learning and an expert database, and the system comprises a multi-source data processing module which is used for processing and standardizing the molecular structure, genome characteristics and clinical data of a drug; the expert knowledge base comprises drug attributes, disease characteristics and clinical guidelines; the prediction model cluster is composed of a deep neural network, an integrated learning model and a symbol inference engine and used for predicting the IC50 value, the clinical response rate and the adverse reaction probability of the medicine; the dynamic optimization module is used for uncertainty quantification of the model, incremental learning of a training set and dynamic updating of a knowledge base; and the interpretability output module is used for interpreting the prediction result and visually outputting the prediction result.

The embodiment of the invention provides a medicine evaluation method and related equipment, and belongs to the technical field of information processing. The method comprises the following steps: acquiring medicine input information corresponding to a first medicine; the first medicine is any medicine, and the medicine input information comprises medicine type data; generating a corresponding medicine evaluation template according to medicine type data in the medicine input information; collecting expert evaluation information corresponding to the first drug through the drug evaluation template; the expert evaluation information comprises text data and score data; and performing text analysis on the text data corresponding to the first drug through the drug evaluation model to generate a model evaluation score, and integrating the model evaluation score and the score data to obtain a target evaluation result corresponding to the first drug. According to the embodiment of the invention, the consistency and objectivity of the drug evaluation result can be remarkably improved, so that more comprehensive and intelligent decision support is provided for drug selection of medical institutions.

The invention relates to the technical field of disease animal models, in particular to a construction method, an evaluation method and application of a bipolar affective disorder liver stagnation and spleen deficiency syndrome combined animal model. According to the method, a liver depression and spleen deficiency syndrome modeling method is adopted for model construction, evaluation indexes are formulated by combining manic and depression behavior expressions of mice and innovatively combining typical expressions of liver depression and spleen deficiency, a liver depression and spleen deficiency syndrome animal model evaluation method is explored, and a thought is provided for achieving standardization and normalization of liver depression and spleen deficiency syndrome model evaluation. The modeling method is simple and economical, provides an experimental animal model for syndrome differentiation treatment of diseases, particularly provides a corresponding animal model for traditional Chinese medicine syndrome differentiation treatment and new drug pharmacological experiments, accelerates the progress of traditional Chinese medicine disease syndrome research and new drug development, provides technical service for drug evaluation, and has great application value.

The invention relates to the technical field of digital medical treatment and drug evaluation, in particular to an individualized drug curative effect and safety evaluation method and system based on digital twinborn and causal reinforcement learning. Individualized anti-fact prediction is realized through a patient digital twinning model, and potential curative effects and adverse event risks of different medication schemes can be evaluated on a single patient level. Meanwhile, an off-strategy causal reinforcement learning and dual-robust estimation method is adopted, the individualized value of a long-term sequential medication strategy is evaluated from observed real world data, and the preciseness of causal inference is improved; in addition, a curative effect-safety joint value function is constructed, curative effect benefits, safety risks and compliance cost are uniformly incorporated into the same decision framework, and multi-objective joint optimization is achieved; finally, an interpretability analysis report containing key features, value comparison and risk analysis is provided, the understanding and trust of clinicians on recommendation results are enhanced, and application and popularization in clinical practice are facilitated.

The invention relates to the field of drug evaluation methods, and provides a method for establishing a zebra fish myopia model and application thereof in order to solve the problems of high modeling cost, long time consumption and few characterization indexes of an animal myopia model in the prior art, the zebra fish myopia model is established by injecting a zebra fish lumican gene MO into a zebra fish body for induction, and the zebra fish lumican gene MO is used as an animal myopia model. And after modeling, evaluating the myopia prevention and treatment effects of the medicine to be detected through analyzed eyeball shapes, eye cell apoptosis conditions and behavioral change indexes of the zebra fish. The zebrafish myopia model is high in modeling speed and stable in modeling effect, and can be used for rapidly screening medicines with the effects of preventing and treating myopia and researching the action ways of the medicines.

The present application relates to the technical field of digital medicine and drug evaluation, and particularly relates to an individualized drug efficacy and safety evaluation method and system based on digital twinning and causal reinforcement learning. Through a patient digital twinning model, individualized counterfactual prediction is realized, which can evaluate the potential efficacy and adverse event risk of different drug regimens at the individual patient level. Meanwhile, off-policy causal reinforcement learning and double robust estimation methods are used to evaluate the individualized value of long-term sequential drug strategies from observational real-world data, improving the rigor of causal inference. In addition, a combined efficacy-safety value function is constructed, which unifies efficacy benefits, safety risks, and compliance costs into the same decision framework, enabling multi-objective joint optimization. Finally, an interpretable analysis report is provided, including key features, value comparisons, and risk analyses, which enhances clinicians' understanding and trust in the recommended results, facilitating the application in clinical practice.

The present invention provides a technology for creating functional inner ear stria vascularis marginal cells that are potentially applicable for screening of chemical agents and pathological analysis of hearing impairment. This method for producing inner ear stria vascularis marginal cells comprises a step for culturing a cell population including inner ear precursor cells, in an insulin-free culture medium that does not contain insulin or contains insulin only in a trace amount.

An object of the present invention is to provide a drug evaluation method using myocardial cells, which can stably evaluate an effect of a drug such as a muscarinic receptor agonist, an adrenergic receptor inhibitor or a muscarinic receptor inhibitor on a heart rate; and a reagent and a kit for carrying out the drug evaluation method. According to the present invention, there is provided a drug evaluation method including: treating myocardial cells with a culture medium containing a physiologically active substance of a sympathetic nervous system and / or a physiologically active substance of a parasympathetic nervous system; bringing a drug into contact with the myocardial cells treated as above; and evaluating an effect of the drug on a heart rate of the myocardial cells.

The present application relates to the technical field of bioinformatics and drug evaluation, and particularly relates to a method for constructing an organoid drug sensitivity evaluation model based on multi-omics fusion, comprising synchronously collecting morphokinetic time sequence images and multi-time point single-cell multi-omics data of organoids, obtaining paired morphological and molecular dynamic data, extracting cell state factors through coupled non-negative tensor decomposition, constructing a non-equilibrium free energy landscape under drug disturbance, quantifying the loss degree of molecular system robustness from two dimensions of geometric deformation and topological structure, detecting cross-scale causal relationships and constructing a drug disturbance entropy index. In the present application, the drug effect is evaluated from the physical nature of the loss of biological system robustness, replacing the traditional correlation analysis method, realizing the unification of quantitative evaluation of drug sensitivity and explanation of the mechanism of action, effectively distinguishing drug specific action and non-specific stress, and being suitable for personalized tumor treatment and new drug research and development.

The invention discloses application of a miR-6809-5p inhibitor, and belongs to the technical field of biological medicine.The inventor finds that expression of miR-6809-5p in plasma of a PD patient is abnormally increased in the research of PD pathogenesis, and further cell experiments find that the expression of miR-6809-5p is abnormally increased in the plasma of the PD patient. By inhibiting the expression of the miR-6809-5p, the adverse effects of MPP + on cell viability, apoptosis, ROS, p-alpha-syn and TH protein can be effectively improved, and the miR-6809-5p has a remarkable treatment effect on PD. MPP + is an active metabolite of neurotoxin MPTP, can be selectively absorbed by dopaminergic neurons through dopamine transporter (DAT) protein to trigger degeneration death of the dopaminergic neurons, and is widely applied to construction of PD cell models to research pathogenesis of PD and drug evaluation. The miR-6809-5p inhibitor disclosed by the invention is used for preparing a medicine for treating the Parkinson's disease, and the nucleotide sequence of the miR-6809-5p inhibitor is as follows: UGAUCCUUUCUUUCCUUGCCA.

The purpose of the present invention is to provide a method for evaluating a drug using myocardial cells and with which it is possible to stably evaluate the effect of a drug such as a muscarinic receptor agonist, an adrenergic receptor inhibitor, and a muscarinic receptor inhibitor on the heart rate. And a reagent and a kit for performing the method for evaluating the drug. According to the present invention, provided is a method for evaluating a drug, comprising: a step for treating myocardial cells with a culture medium containing a physiologically active substance of the sympathetic nervous system and / or a physiologically active substance of the parasympathetic nervous system; a step in which a drug is brought into contact with the treated myocardial cells; and evaluating the influence of the drug on the heart rate of the myocardial cells.

An anticancer drug assessment method includes culturing a cell structure including stromal cells in which a gene encoding a live cell marker protein has been knocked out and cancer cells in the presence of an anticancer drug, and assessing the anticancer drug using an expression level of the live cell marker protein as an index in this order. In the assessment, the expression level of the live cell marker protein is measured using a culture supernatant, or in the assessment, a substance that fluoresces or produces color when reacted with the live cell marker protein is added, and the expression level of the live cell marker protein is measured based on the amount of fluorescence or coloration of the substance.

The invention discloses a construction method and application of an anxiety disorder model based on peer pressure stimulation, and belongs to the field of animal models. The model construction method comprises the following steps: (1) experimental animal adaptation; (2) introducing resources and social elements; and (3) establishing a peer pressure scene. According to the method, through the steps of same nest adaptation-resource and social contact introduction-resource and social contact separation to form resource and social contact differences, the scene that the pressure of the peers is generated due to non-uniform resource and social contact relationship distribution in human life is accurately simulated, and the scene is highly matched with the actual attack inducement of human anxiety disorder; the physiological process of pressure-induced anxiety of the peers can be reflected more truly, and a more reliable model is provided for research on pathogenesis of human anxiety disorder and drug evaluation. The method is easy to operate and non-invasive, interference of non-experimental factors on mouse behaviors can be reduced to the maximum extent, and reliability and repeatability of the model are guaranteed.

The application relates to the field of drug evaluation, and discloses a method for establishing a zebrafish cancer-related fatigue model to solve the problems of the existing technology, such as difficulty in controlling the dosage of a chemotherapeutic drug, more cumulative toxicity of experimental animals, easy death, long modeling time, small flux and difficult operation, and the method comprises the following steps: selecting normal development zebrafish 4 days after fertilization, placing the zebrafish in a microwell plate, dividing the zebrafish into a normal control group and a model group, injecting the zebrafish in the model group with vinorelbine tartrate injection through intravenous injection, and not treating the normal control group; culturing the normal control group and the model group in a zebrafish culture solution at a constant temperature; comparing the total movement distance of the zebrafish in the control group and the model group; if the total movement distance of the zebrafish in the model group is significantly less than that of the normal control group, then the zebrafish cancer-related fatigue model is successfully established. The model is short in time required for establishment, simple in operation, and can realize efficient and high-flux evaluation of the anticancer-related fatigue effect of a drug.

The invention belongs to the technical field of in-vitro drug evaluation model construction, and particularly relates to bio-ink, an in-vitro humanized neural model and application of the bio-ink in construction of an opioid drug classification prediction model and a dose-effect relationship. The bio-ink comprises a neuroma cell line, methacrylated gelatin, a photoinitiator and a basement membrane matrix. The in-vitro humanized neural model prepared on the basis of the bio-ink provided by the invention has cell-cell and cell-matrix microenvironment interaction characteristics, the complexity of in-vivo tissues can be more truly reduced, and the structure and function of human neurons can be highly biomimetic simulated on the cellular level; the biomimetic property is obviously superior to that of traditional two-dimensional culture and animal experiments, and the accuracy and reliability of drug toxicity and dependency evaluation are improved.

To provide a culture device, a method for producing a culture, and a method for evaluating a medicine, which are excellent in versatility.SOLUTION: Provided is a culture device for co-cultivating a first cell culture and a second cell culture. The culture device comprises a main body in which a culture space capable of culturing under anaerobic conditions is formed. The main body has an opening that opens from the culture space to the outside of the main body, and a porous body provided in the opening. The first cell culture is held in the porous body so as to cover the culture space side of the porous body. The second cell culture is cultured in the culture space. The main body is configured such that the culture space can be closed from the outside of the main body except for the opening.SELECTED DRAWING: Figure 1

The application provides a biosensing probe for double-target linkage monitoring, which is based on an NH2-UiO-66@AuNPs nanocomposite material, double-monitoring marker recognition aptamers are connected to the base material, the double-monitoring marker aptamers are used to connect monitoring markers, the monitoring markers are IL-6 and CRP; AuNPs are in-situ synthesized on the surface of NH2-UiO-66 to form an NH2-UiO-66@AuNPs nanocomposite material as a base material; IL-6 aptamers and CRP aptamers are connected to the NH2-UiO-66@AuNPs through Au-S bonds; the IL-6 aptamers are complementary to IL-6 cDNA to form a double-stranded structure, and a first fluorescent dye is connected to the IL-6 cDNA; the CRP aptamers are complementary to CRP cDNA to form a double-stranded structure, and a second fluorescent dye is connected to the CRP cDNA. The double-target linkage monitoring biosensing probe provided by the application provides a promising platform for the synchronous tracking of double indicators, which can not only be used for mechanism verification in drug discovery, but also be used for companion diagnosis to tailor treatment programs.

The present application relates to the technical field of drug evaluation, and discloses a kind of blood tumor targeted drug curative effect dynamic evaluation method and system.The method comprises: by obtaining the feedback parameter containing action index and physiological index after targeted drug administration, and the difference calculation of feedback parameter and the benchmark feedback parameter under the condition of not being administered to output deviation parameter, and then generate drug efficacy fluctuation signal or risk early warning signal;And generate curative effect evaluation report based on drug efficacy fluctuation signal or risk early warning signal.The present application realizes the dynamic quantitative evaluation of curative effect by establishing the benchmark control of patient itself, objectively reflects the net effect of drug on patient, provides reliable individualized data basis for curative effect evaluation, improves the objectivity and accuracy of evaluation;And by filtering out random noise and transient fluctuation in data, ensure that the identified change starting point has high confidence, improve the accuracy and reliability of key event capture in dynamic evaluation process.

The application discloses a kind of based on the natural multi-modal behavior of home cage depression state and drug evaluation method of dog, comprising the following steps: 1) basic data acquisition;2) natural behavior observation in home cage;3) experimental grouping and drug treatment;4) depression state grading and evaluation;And 5) efficacy evaluation standard and evaluation.This method takes beagle as model, through the three-level evaluation process of "basic physiological index-free activity behavior-social interaction behavior", realizes the standardized evaluation of dog depression state and drug efficacy.Compared with traditional unfamiliar environment single test, this method carries out longitudinal observation in familiar environment, can avoid the interference of environmental stimulation on animal emotion, more truly reflects basic emotional state, fills the technical blank of dog natural behavior quantitative evaluation.

The invention discloses a tumor immune drug evaluation method and system, and belongs to the field of tumor immunotherapy and drug screening evaluation.The tumor immune drug evaluation method comprises the steps that S1, tumor slices of ten III-stage non-small cell lung cancer patients are collected, and 8 kinds of immune markers are marked through mIF to obtain space information; s2, constructing a cellular-level spatial atlas based on a deep network and a clustering algorithm, and extracting topological indexes; s3, identifying six types of immune microenvironment modes; s4, carrying out in-situ co-culture on CD8 + T cells and tumor cells, and recording dynamic data of image omics and immune factors; s5, constructing a Bi-RNN disturbance response model to extract a joint score; s6, iteratively updating score distribution by adopting Bayesian modeling and a Gaussian kernel function; s7, performing triple cross validation on the drugs 10% before scoring; s8, screening the fluctuation rate lt; 0.15, the heterogeneity score change lt; 10% of drugs are used as stable candidates. The method has the beneficial effects that high-throughput precise evaluation and stable screening of the efficacy of the tumor immune drug are realized.

The technical scheme of the invention discloses an orthopedics-related drug patent value evaluation system, which is characterized by comprising an orthopedics-related drug evaluation reference standard data acquisition module; an orthopedic related drug patent data integration module; a multi-source data feature construction module; an orthopedic related drug patent comprehensive value evaluation model; and an evaluation and result output module. According to the system disclosed by the invention, traditional patent evaluation indexes such as law, economy and technology can be combined with clinical effects, scientific research, medicine and health policies, supervision systems and the like of orthopedic drugs, so that dynamic evaluation and prospective prediction of the patent values of the orthopedic related drugs are realized. Meanwhile, multi-source data acquisition and an advanced machine learning algorithm are introduced, data scientificity and rationality are improved by using multiple model methods, an evaluation system exclusive to the orthopedics-related pharmaceutical industry is constructed, a closed-loop process of achievement transformation-patent value evaluation is formed, and scientificity, adaptability and practicability of evaluation results are ensured.

The present application discloses a method and a system for drug evaluation. Among them, the method includes: obtaining original imaging data corresponding to a target area under electric field stimulation, wherein the target area includes a plurality of cells to be tested cultured with a candidate drug, and the plurality of cells to be tested have fluorescence labels; determining a target fluorescence change commonly corresponding to the plurality of cells to be tested from the original imaging data, wherein the target fluorescence change is used to quantitatively represent the average change degree of the membrane potential of the plurality of cells to be tested under electric field stimulation; evaluating the candidate drug according to the target fluorescence change to obtain an evaluation result. The present application solves the technical problem that the drug screening method in the related art has low evaluation efficiency due to the limitation of throughput in the evaluation of cell electrophysiological characteristics.

The present invention relates to a nanodot sensor for drug screening, a manufacturing method therefor, a drug screening method using same, and a drug screening method for preventing or treating glioblastoma using same. When the nanodot sensor for drug screening according to the present disclosure is used, a glioblastoma–midbrain assembloid is cultured in an adhesive hydrogel containing neurotrophic factor-3-conjugated gold nanoparticles, thereby resolving limitations of conventional assembloid culture in which adhesion between assembloids was not well maintained during long-term culture, enhancing neural connectivity between the two organoids, and facilitating accurate electrophysiological signal analysis by a conductive material. In addition, the flexible-structured nanodot electrode increases a contact surface area with the assembloid, thereby enabling simultaneous, accurate, and non-invasive measurement of electrophysiological signals from each organoid. Accordingly, effective drug screening can be performed in an assembloid model.

1. The name of the design product: electronic device's drug evaluation task recruitment graphical user interface. 2. The use of the design product: an electronic device. 3. The design points of the design product: in the graphical user interface. 4. The picture or photo that best indicates the design points: front view. 5. Planar product, omit other views. 6. The use of the graphical user interface: for publishing recruitment announcements of drug evaluation information. 7. The human-computer interaction mode of the graphical user interface: the front view is the main page of the drug evaluation task recruitment graph; the change state diagram 1 is the page displayed after the user clicks "I want to recruit" on the right upper side of the front view; the change state diagram 2 is the page displayed after the user fills in the corresponding recruitment information and clicks "submit immediately".

The invention discloses an intelligent evaluation method and system for drug curative effect and toxicity based on multi-modal pathological data fusion, and relates to the technical field of drug evaluation systems. Comprising the steps that biological characteristic data under the action of a target drug is collected, a multi-modal characteristic vector is constructed, and the biological characteristic data comprises an animal experiment data source, an in-vitro experiment data source and a public database or existing research data. According to the method, quantitative analysis is carried out on changes of multi-modal features in the time dimension, features reflecting focus improvement, immune activation and curative effect stability are fused, and curative effect indexes are constructed; meanwhile, weighted integration is carried out on characteristics reflecting tissue damage, immune imbalance and toxicity related effects, toxicity indexes are constructed, and on the basis, multi-dimensional comprehensive judgment of the drug action effect is realized by establishing a combined evaluation system of curative effect and toxicity, and quality grades of different drug schemes are divided in a visual mode.

The invention provides an evaluation method of a medicine for treating lung inflammatory diseases and application thereof, and relates to the technical field of medicine evaluation and screening, and the evaluation method comprises the following steps: obtaining evaluation index data of a to-be-evaluated medicine corresponding to a treatment stage to obtain a corresponding evaluation index treatment result, and scoring the to-be-evaluated medicine according to the evaluation index treatment result, and calculating the total score of the treatment stage corresponding to the evaluation index, if the total score is less than 2, determining that the treatment effect of the to-be-evaluated drug is unqualified, and if the score is greater than or equal to 2, determining that the treatment effect of the to-be-evaluated drug is qualified, thereby realizing quantitative evaluation of the treatment effects of the to-be-evaluated drug in different treatment stages, facilitating drug administration stage allocation, and improving the efficiency. And judging whether the medicine is stage medicine or long-term medicine. The technical problem that in the prior art, a method for evaluating the lung disease treatment medicine in multiple aspects does not exist is solved. According to the method, the defect of long time of an in-vivo model is overcome, limitation and instability of a single method are overcome from multiple indexes, and guarantee is provided for in-vitro screening of drugs.

This invention relates to a progressive pathological animal model for drug evaluation and its construction method, belonging to the field of experimental animal model technology. Addressing the shortcomings of existing models, such as their inability to simulate progressive clinical disease courses, low model success rate, large individual variability, and low fit with clinicopathological features, this invention employs a sequential three-stage synergistic induction modeling method. This method sequentially induces basal metabolic abnormalities, subclinical cardiorenal injury, and progressive cardiorenal fibrosis, accurately matching the natural course of human diseases. This method is simple to operate, requires no complex surgery, and produces a model with a high model success rate, low mortality rate, good uniformity, and a high degree of fit between pathological features and clinical findings. It can be used for screening drugs for the treatment of this disease, evaluating drug efficacy, and studying the mechanism of action.

1. Name of the Design Product: Graphical User Interface of the Drug Evaluation Information Sharing Platform for Electronic Devices. 2. Use of the Design Product: An electronic device. 3. Design Key Points of the Design Product: Lies in the graphical user interface. 4. Picture or Photo Best Showing the Design Key Points: Front View. 5. For planar products, other views are omitted. 6. Use of the Graphical User Interface: Used to query evaluation information of various drugs. 7. Human - Machine Interaction Method of the Graphical User Interface: The front view is the main page of the national medical institution drug evaluation information data sharing platform; the interface change state diagram 1 is the page displayed after the user enters and / or selects the corresponding query information in the front view and clicks "I want to register" in the upper - right corner of the front view; the interface change state diagram 2 is the page displayed after the user scrolls down the middle mouse wheel or drags the right - hand scroll bar down in the interface change state diagram 1; the interface change state diagram 3 is the page displayed after the user fills in the corresponding information in the interface change state diagram 2 and clicks "Submit immediately".

The application belongs to the technical field of in vitro drug evaluation model construction, and particularly relates to a biological ink, an in vitro humanized nerve model and application of the in vitro humanized nerve model in construction of an opioid drug classification prediction model and dose-effect relationship. The biological ink comprises a neuroblastoma cell line, methacrylated gelatin, a photoinitiator and a basement membrane matrix. The in vitro humanized nerve model prepared based on the biological ink provided by the application has microenvironment interaction characteristics of cell-cell and cell-matrix, can more truly restore the complexity of in vivo tissues, can highly bionically simulate the structure and function of human neurons at the cell level, the bionicity is significantly better than traditional two-dimensional culture and animal experiments, and the accuracy and reliability of drug toxicity and dependence evaluation are improved.